Ipilimumab

Ipilimumab targets the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) receptor, enhancing the immune response against the tumor mass.
Genova et al. 2012 Expert Opin. Biol. Ther. 12(7): 939-948
Redman et al., 2016

Ipilimumab is a fully human monoclonal antibody that blocks Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) to augment antitumor T-cell responses.
Lacouture et al., 2014

Ipilimumab Active Particularly in Pts with Small & Asymptomatic Brain Metastases
Maio et al. 2013

see also:
Anti-CTLA-4 / CTLA-4 antibodies